This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Blueprint Medicines (BPMC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Blueprint Medicines Expediates Filings for Key Candidates
by Zacks Equity Research
Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 52.67% and 1199.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.
Company News For Dec 12, 2017
by Zacks Equity Research
Companies in the news are: KMG,ARGX,BPMC,BLUE
Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session
by Zacks Equity Research
Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
3 Biotech Stocks That Are Broker Favorites
by Arpita Dutt
These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).
Can The Uptrend Continue for Blueprint Medicines (BPMC)?
by Zacks Equity Research
Investors certainly have to be happy with Blueprint Medicines Corporation (BPMC) and its short term performance
Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation (BPMC) may be one such company.
Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.
Quest Diagnostics (DGX) Q4 Earnings: What Lies in Store?
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) is scheduled to report fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 26, 2017.
Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) is scheduled to report fourth-quarter 2016 results on Jan 26, before the opening bell.
ResMed (RMD) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report second-quarter fiscal 2017 results, after market close on Jan 23.
Blueprint Medicines (BPMC) Shares March Higher, Can It Continue?
by Zacks Equity Research
Blueprint Medicines Corporation (BPMC) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday